IN2014DN04226A - - Google Patents

Info

Publication number
IN2014DN04226A
IN2014DN04226A IN4226DEN2014A IN2014DN04226A IN 2014DN04226 A IN2014DN04226 A IN 2014DN04226A IN 4226DEN2014 A IN4226DEN2014 A IN 4226DEN2014A IN 2014DN04226 A IN2014DN04226 A IN 2014DN04226A
Authority
IN
India
Prior art keywords
subject
depression
effectiveness
treating
resistant
Prior art date
Application number
Inventor
Maurizio Fava
George Papakostas
Jr Harold O Koch
David Kronlage
Original Assignee
Gen Hospital Corp
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Nestec Sa filed Critical Gen Hospital Corp
Publication of IN2014DN04226A publication Critical patent/IN2014DN04226A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Disclosed herein are novel assays, systems and kits for selecting a treatment regimen for a subject with depression by identifying at least one nucleic acid polymorphism, e.g., but not limited to, at the MTHFR, MTR, or MTRR locus, and/or determin ing expression levels of peripheral biomarkers (e.g., SAM, SAH, and 4-HNE) in a test sample from a human subject. These biomarkers can be used to determine the effectiveness of treating a depressed subject with a folate-containing compound (alone or as an adjunct to an antidepressant). Additionally, these bio markers can be used to select an appropriate treatment regimen for subjects with treatment-resistant depression (e.g., resistant to at least one selective serotonin re uptake inhibitor). Methods and compositions for treating a subject with depression and/or determining or improving the effectiveness of an antidepressant drug taken by a subject are also provided herein.
IN4226DEN2014 2011-11-14 2012-11-14 IN2014DN04226A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559541P 2011-11-14 2011-11-14
PCT/US2012/065084 WO2013074676A2 (en) 2011-11-14 2012-11-14 Assays and methods for selecting a treatment regimen for a subject with depression

Publications (1)

Publication Number Publication Date
IN2014DN04226A true IN2014DN04226A (en) 2015-05-22

Family

ID=47279072

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4226DEN2014 IN2014DN04226A (en) 2011-11-14 2012-11-14

Country Status (14)

Country Link
US (2) US9540691B2 (en)
EP (1) EP2780467B1 (en)
JP (1) JP6285865B2 (en)
KR (1) KR102035877B1 (en)
CN (1) CN104053785A (en)
AU (1) AU2012340015B2 (en)
BR (1) BR112014011491A2 (en)
CA (1) CA2855640C (en)
HK (1) HK1202590A1 (en)
IL (1) IL232407B (en)
IN (1) IN2014DN04226A (en)
MX (1) MX354547B (en)
RU (1) RU2622082C2 (en)
WO (1) WO2013074676A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104053785A (en) * 2011-11-14 2014-09-17 综合医院公司 Assays For Selecting A Treatment Regimen For A Subject With Depression And Methods For Treatment
BR112015022820A8 (en) * 2013-03-12 2019-11-26 Nestec Sa trial to select a treatment regimen for an individual with depression, use of a compound comprising folate, composition and kit
CN105073096A (en) 2013-03-15 2015-11-18 詹森药业有限公司 Pharmaceutical composition of S-ketamine hydrochloride
US20150250813A1 (en) * 2013-12-05 2015-09-10 Buriva, LLC Dietary supplement containing phospholipid-dha, folate, and n-acetyl-l-cysteine
US9610302B2 (en) * 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9549937B2 (en) * 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
AU2015227296A1 (en) * 2014-03-05 2016-09-08 Takeda Pharmaceutical Company Limited Method for treating depression and major depressive disorder
WO2015136446A1 (en) * 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
KR101588119B1 (en) * 2014-05-16 2016-01-25 동아대학교 산학협력단 63 DNA Typing Kits and Diagnostic Kits for Detecting Diseases Related to Polymorphic Microsatellites of 63 Gene
AU2015301782B2 (en) 2014-08-13 2020-09-03 Janssen Pharmaceutica Nv Method for the treatment of depression
CA2961208A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
CN105671130A (en) * 2014-11-18 2016-06-15 武汉白原科技有限公司 Psychology-personality detection kit and method
US20160203591A1 (en) * 2015-01-09 2016-07-14 Umm Al-Qura University System and process for monitoring the quality of food in a refrigerator
CN104655705B (en) * 2015-02-12 2017-03-08 江苏省原子医学研究所 A kind of method of catechol oxygen methyl transferring enzyme COMT activity in use capillary electrophoresis quick detection biological specimen
CN104789668A (en) * 2015-04-10 2015-07-22 浙江博惠生物科技有限公司 Detection PCR amplification primers of detection site rs1801394 for folate metabolism capability assessment and single base extension primer
US11122997B2 (en) 2015-04-17 2021-09-21 Mayo Foundation For Medical Education And Research Modulating the aryl hydrocarbon receptor system to treat major depressive disorder
WO2016176458A1 (en) * 2015-04-28 2016-11-03 Proove Biosciences, Inc. System and method for processing genotype information relating to opiod risk
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CA2987292A1 (en) * 2015-05-25 2016-12-01 Hunan Skyworld Biotechnologies Co. Ltd. Use of fluorescence for the quick and easy determination of s-adenosylmethionine, s-adenosylhomocysteine and homocysteine
US11313868B2 (en) 2016-06-14 2022-04-26 Board Of Regents, The University Of Texas System Methods of detecting anti-folic acid antibodies and uses thereof
WO2018053605A1 (en) * 2016-09-26 2018-03-29 Precision Medicine Holdings Pty Ltd Diagnosis, prognosis and treatment for schizophrenia and schizoaffective psychosis
CN107245527A (en) * 2017-07-25 2017-10-13 重庆京因生物科技有限责任公司 Primer, molecular beacon, kit and its detection method of MTRR gene pleiomorphism quick detections
WO2019027568A1 (en) * 2017-08-02 2019-02-07 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Wearable device and application for behavioral support
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
KR20200113197A (en) 2017-12-22 2020-10-06 얀센 파마슈티칼즈, 인코포레이티드 Esketamine for treatment of depression
CN108251522B (en) * 2018-04-09 2020-11-27 江苏硕世生物科技股份有限公司 Human MTHFR and MTRR gene detection kit and application thereof
CN108642138B (en) * 2018-05-02 2021-11-30 广东药科大学 Method and kit for detecting genetic information of folate metabolism related gene
EP3788644A4 (en) 2018-05-03 2023-03-01 L. Pierre De Rochemont High speed / low power server farms and server networks
CN112514061A (en) 2018-06-05 2021-03-16 L·皮尔·德罗什蒙 Module with high peak bandwidth I/O channel
CN108823299A (en) * 2018-06-11 2018-11-16 苏州艾达康医疗科技有限公司 A kind of detection method and kit of depression medication related gene
KR20210081335A (en) * 2018-09-03 2021-07-01 비스비 메디컬, 인코포레이티드 Apparatus and method for antibiotic susceptibility test
JP2022524008A (en) 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド Esketamine for the treatment of depression
CN114375339A (en) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 TL1A patient selection method, system and device
CN110148461B (en) * 2019-06-26 2021-09-21 周建勋 Module switching system for multi-parameter measurement
CN110693507A (en) * 2019-08-30 2020-01-17 中国民用航空飞行学院 System for testing psychological health and psychology aid of civil aviation flight trainees
CN111351945B (en) * 2020-03-18 2021-04-23 东南大学 Application of vitamin D binding protein as marker in diagnosis of mental disease depression
WO2022115277A1 (en) * 2020-11-24 2022-06-02 Genomind, Inc. Methods and systems for reporting patient-and drug-specific medical data
CN116103385A (en) * 2021-11-11 2023-05-12 中国科学院深圳理工大学(筹) Gene diagnosis kit and system for predicting response of depressive disorder patient to treatment
CN116298233A (en) * 2022-03-16 2023-06-23 昱言科技(北京)有限公司 Biomarkers for diagnosing bipolar disorder
WO2023220213A1 (en) * 2022-05-11 2023-11-16 Higgins Evelyn Methods for providing a personalized therapeutic treatment regime for addictions

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US548257A (en) 1895-10-22 Hay rake and loader
US3837376A (en) 1971-06-01 1974-09-24 Metropolitan Pathology Labor I Blood serum collection tube and method
US4336185A (en) 1976-03-02 1982-06-22 Rohm And Haas Company Folic acid derivatives
US4120448A (en) 1977-06-08 1978-10-17 Baxter Travenol Laboratories, Inc. Centrifugal liquid processing apparatus with automatically positioned collection port
US4656035A (en) 1984-12-21 1987-04-07 University Of Tennessee Research Corporation Method of separating blood platelets
US4946773A (en) 1985-12-23 1990-08-07 President And Fellows Of Harvard College Detection of base pair mismatches using RNAase A
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Method and kits for the amplification and detection of nucleic acid sequences
WO1989006700A1 (en) 1988-01-21 1989-07-27 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
WO1989010414A1 (en) 1988-04-28 1989-11-02 Robert Bruce Wallace AMPLIFIED SEQUENCE POLYMORPHISMS (ASPs)
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5925525A (en) 1989-06-07 1999-07-20 Affymetrix, Inc. Method of identifying nucleotide differences
GB2236186B (en) 1989-08-22 1994-01-05 Finnigan Mat Gmbh Process and device for laser desorption of analyte molecular ions, especially of biomolecules
US5045694A (en) 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
US6013431A (en) 1990-02-16 2000-01-11 Molecular Tool, Inc. Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
US5846710A (en) 1990-11-02 1998-12-08 St. Louis University Method for the detection of genetic diseases and gene sequence variations by single nucleotide primer extension
DE69132843T2 (en) 1990-12-06 2002-09-12 Affymetrix Inc N D Ges D Staat Identification of nucleic acids in samples
US5169766A (en) 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5994069A (en) 1996-01-24 1999-11-30 Third Wave Technologies, Inc. Detection of nucleic acids by multiple sequential invasive cleavages
DK0700521T3 (en) 1993-05-28 2003-09-29 Baylor College Medicine Process and mass spectrometer for desorption and ionization of analyzers
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US6136540A (en) 1994-10-03 2000-10-24 Ikonisys Inc. Automated fluorescence in situ hybridization detection of genetic abnormalities
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5851770A (en) 1994-04-25 1998-12-22 Variagenics, Inc. Detection of mismatches by resolvase cleavage using a magnetic bead support
US6566065B1 (en) 1994-05-26 2003-05-20 Mcgill University Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene
GB9410620D0 (en) 1994-05-26 1994-07-13 Univ Mcgill cDNA for human mehylenetetrahydrofolate reductase
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
US5849483A (en) 1994-07-28 1998-12-15 Ig Laboratories, Inc. High throughput screening method for sequences or genetic alterations in nucleic acids
US5866337A (en) 1995-03-24 1999-02-02 The Trustees Of Columbia University In The City Of New York Method to detect mutations in a nucleic acid using a hybridization-ligation procedure
US5704888A (en) 1995-04-14 1998-01-06 Cobe Laboratories, Inc. Intermittent collection of mononuclear cells in a centrifuge apparatus
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5928870A (en) 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
WO1999013108A1 (en) 1997-09-10 1999-03-18 University Of Maryland, Baltimore Method of amplifying dna and rna mismatch cleavage products
ATE369135T1 (en) * 1998-04-24 2007-08-15 Scarista Ltd TREATMENT OF DEPRESSION AND COMPOSITIONS THEREOF
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
CN1406126A (en) 1998-10-01 2003-03-26 诺瓦提斯公司 New sustained release oral formulations
US6395481B1 (en) 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
US6618679B2 (en) 2000-01-28 2003-09-09 Althea Technologies, Inc. Methods for analysis of gene expression
WO2001066172A2 (en) 2000-03-09 2001-09-13 Gambro, Inc. Extracorporeal blood processing method and apparatus
US20020016293A1 (en) 2000-04-21 2002-02-07 Ratain Mark J. Flavopiridol drug combinations and methods with reduced side effects
DE10022510A1 (en) 2000-05-10 2001-11-15 Basf Ag Composition used as folate source in food, feed, nutritional supplements or medicaments, e.g. for prophylaxis of cardiovascular disease includes folic acid and 5-methyl-tetrahydrofolic acid
US6355433B1 (en) 2000-06-02 2002-03-12 Dna Sciences, Inc. Determination of nucleotide sequence variations through limited primer extension
WO2002006231A1 (en) 2000-07-18 2002-01-24 Sumitomo Pharmaceuticals Co., Ltd. Serotonin reuptake inhibitors
AU2002240066A1 (en) 2001-01-26 2002-08-06 University Of Chicago Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
US20030077616A1 (en) 2001-04-19 2003-04-24 Ciphergen Biosystems, Inc. Biomolecule characterization using mass spectrometry and affinity tags
US20030100476A1 (en) 2001-05-11 2003-05-29 Weinberger Daniel R. Effect of COMT genotype on frontal lobe function
EP1390497A2 (en) 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
IL160324A0 (en) 2001-08-13 2004-07-25 Beyond Genomics Inc Method and system for profiling biological systems
UA81749C2 (en) 2001-10-04 2008-02-11 Х. Луннбек А/С Derivated of phenylpiperazine as serotonin reuptake inhibitorS
IL163645A0 (en) 2002-02-21 2005-12-18 Idgene Pharmaceuticals Ltd Association of snps in the comt locus and neighboring loci with schizophrenia, bipolar disorder, breast cancer and colorectal cancer
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
US7241281B2 (en) 2002-04-08 2007-07-10 Thermogenesis Corporation Blood component separation method and apparatus
US20030194711A1 (en) 2002-04-10 2003-10-16 Matthew Zapala System and method for analyzing gene expression data
US20030199001A1 (en) 2002-04-23 2003-10-23 Pitt Aldo M. Sample preparation of biological fluids for proteomic applications
US20030205538A1 (en) 2002-05-03 2003-11-06 Randel Dorian Methods and apparatus for isolating platelets from blood
CA2415154C (en) 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
US20040203034A1 (en) 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
DE602004031512D1 (en) 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc POLYMERIC IMPLANT FOR DELAYED RELEASE OF DOPAMINE ANTAGONISTS
US20050054688A1 (en) 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
US20050069936A1 (en) 2003-09-26 2005-03-31 Cornelius Diamond Diagnostic markers of depression treatment and methods of use thereof
EP1732610A2 (en) 2004-03-26 2006-12-20 Baylor University Targeted serotonin reuptake inhibitors
JP2005312435A (en) 2004-03-29 2005-11-10 Kazuhito Rokutan Method for evaluating depression
US20060216737A1 (en) 2005-03-10 2006-09-28 John Bodeau Methods for multiplex amplification
WO2007022248A2 (en) 2005-08-16 2007-02-22 Sloan Kettering Institute For Cancer Research Methods of detection of cancer using peptide profiles
EP1954832A4 (en) 2005-12-06 2009-10-28 Gen Hospital Corp Diagnostic methods for pain sensitivity and chronicity and for tetrahydrobiopterin-related disorders
US20080064702A1 (en) 2006-09-08 2008-03-13 Charalambos Antoniades Use of folates for the prevention and treatment of vascular diseases
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US20100273153A1 (en) 2006-11-29 2010-10-28 Boris Tabakoff Genetic diagnosis of depression
US20090075827A1 (en) 2007-01-19 2009-03-19 Queensland University Of Technology Diagnostic methods and agents
US7947662B2 (en) 2008-02-20 2011-05-24 Gnosis S.P.A. Folates, compositions and uses thereof
US20090307179A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
WO2009131643A1 (en) 2008-04-21 2009-10-29 Monabio, Inc. Immunoassay for specific determination of s-adenosymethionine and analogs thereof in biological samples
MX2010014558A (en) 2008-06-21 2011-07-29 Kenber Llc Dna-directed customization of analgesic compounds as a therapeutic modality.
WO2010060189A1 (en) 2008-11-03 2010-06-03 Newlab Clinical Research Inc. Allele-allele interactions of mthfr gene variants, and uses thereof in predicting disease risk
WO2010138796A2 (en) 2009-05-29 2010-12-02 Genomind, Llc Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis
EP2482677A1 (en) 2009-09-30 2012-08-08 The Regents of The University of California Cofactors and methods for use for individuals
WO2012128799A2 (en) * 2010-12-03 2012-09-27 General Hospital Corporation, The Treating schizophrenia
KR20120092993A (en) 2011-02-14 2012-08-22 지엘팜텍 주식회사 An oral sustained-release tablet comprising tianeptine or pharmaceutically acceptable salts thereof
EP2691081A1 (en) 2011-03-28 2014-02-05 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Sustained-release injectable formulation
MX2014000197A (en) 2011-06-21 2014-06-11 Global Healthcare Focus Llc Methods of preventing or treating disease states related to certain metabolic abnormalities.
US20160058766A1 (en) * 2011-11-14 2016-03-03 Nestec S.A. Assays and methods for selecting a treatment regimen for a subject with depression
CN104053785A (en) 2011-11-14 2014-09-17 综合医院公司 Assays For Selecting A Treatment Regimen For A Subject With Depression And Methods For Treatment

Also Published As

Publication number Publication date
US9546401B2 (en) 2017-01-17
AU2012340015A1 (en) 2014-05-22
US9540691B2 (en) 2017-01-10
US20130267523A1 (en) 2013-10-10
BR112014011491A2 (en) 2017-05-09
US20130172361A1 (en) 2013-07-04
JP2015508281A (en) 2015-03-19
CA2855640A1 (en) 2013-05-23
CN104053785A (en) 2014-09-17
IL232407B (en) 2019-03-31
WO2013074676A2 (en) 2013-05-23
EP2780467A2 (en) 2014-09-24
RU2622082C2 (en) 2017-06-09
EP2780467B1 (en) 2018-10-17
KR20140100524A (en) 2014-08-14
CA2855640C (en) 2020-03-10
MX354547B (en) 2018-03-09
AU2012340015B2 (en) 2017-09-21
NZ624231A (en) 2016-10-28
RU2014124121A (en) 2015-12-27
JP6285865B2 (en) 2018-02-28
WO2013074676A3 (en) 2013-08-15
IL232407A0 (en) 2014-06-30
HK1202590A1 (en) 2015-10-02
KR102035877B1 (en) 2019-10-23
MX2014005786A (en) 2014-08-27

Similar Documents

Publication Publication Date Title
IN2014DN04226A (en)
GB201317477D0 (en) Methods, compositions and kits for determing the presence/absnece of a variant nucleic acid sequence
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
BR112012011230A2 (en) risk factors and prediction of myocardial infarction
BR112013003391A2 (en) pancreatic cancer biomarkers and their uses
BRPI0519570A2 (en) Warfarin dose range determination method for an individual, warfarin dose range determination kit, oligonucleotide or complement thereof, and oligonucleotide arrangement
MX2014000292A (en) Uses of labeled hsp90 inhibitors.
BRPI0919882A8 (en) METHODS TO EVALUATE RNA PATTERNS
EP4249605A3 (en) Methods for analyte detection
BR112012029281A2 (en) anti-human trop-2 antibody having anti-tumor activity in vivo
BRPI0816393A2 (en) METHOD FOR DETERMINING THE NUMBER OF COPIES REGARDING A TARGET POLINUCLEOTIDE SEQUENCE IN A GENOME OF AN INDIVIDUAL
EA201600085A1 (en) KIT FOR DETECTION OF SOYO SYNT SYNT0H2 EVENT
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
EA201590630A1 (en) METHODS OF TREATMENT AND DIAGNOSTICS ASSOCIATED WITH LYZYLOXIDE-LIKE PROTEIN 2 (LOXL2)
EA030186B9 (en) Method for performing quantitation assays
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
BR112012009262A2 (en) A method for inhibiting the proliferation of air-positive cancer cells in an individual diagnosed with or suspected to have air-positive cancer and a method for identifying whether an individual is a candidate for treatment with a composition.
WO2013106844A3 (en) Methods and compositions for the treatment and diaginosis of pancreatic cancer
BR112012018545A2 (en) method of determining and confirming the presence of an hpv in a sample
BR112013033443A2 (en) method for assessing the redox activity of the nucleic acid molecule and the redox activity nucleic acid molecule
BR112017016752A2 (en) methods to determine the risk of endometrial cancer relapse in an individual, to predict relapse in an endometrial cancer individual, to guide treatment in an endometrial cancer individual, to detect microsatellite instability, and to determine cancer subtypes
MX2013004230A (en) Use of signal enhancing compounds in electrochemiluminescence detection.
BR112018069316A2 (en) methods for detecting the presence of at least one pathogenic bordetella species and selecting a patient exhibiting pertussis-like symptoms, and kit for detecting the presence of at least one pathogenic bordetella species.
BR122020012978A8 (en) METHOD OF QUANTIFYING A SPECIFIC PRODUCT IN A CUTTING AND EXTENDING APLIFICATION REACTION (NEAR)